68Ga-PSMA-11 PET/CT for the Diagnosis of Bone Metastases in Patients With Prostate Cancer and Biochemical Progression During Androgen Deprivation Therapy
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04928820|
Recruitment Status : Terminated (slow recruitment)
First Posted : June 16, 2021
Last Update Posted : October 21, 2022
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Biochemically Recurrent Prostate Carcinoma Metastatic Malignant Neoplasm in the Bone Metastatic Prostate Carcinoma Stage IV Prostate Cancer American Joint Committee on Cancer (AJCC) v8 Stage IVA Prostate Cancer AJCC v8 Stage IVB Prostate Cancer AJCC v8||Procedure: Computed Tomography Other: Gallium Ga 68 Gozetotide Procedure: Positron Emission Tomography||Phase 2|
I. To compare the per-patient detection rate of 68Ga-PSMA-11 PET/CT versus bone scan (BS)/CT for M1b in patients treated with androgen deprivation therapy (ADT) who are referred for the imaging evaluation of disease progression.
I. To compare the number of lesions rated as positive for bone metastases between the two imaging tests.
II. To compare the detection rate of 68Ga-PSMA PET/CT versus BS/CT for all M1 disease (M1a or M1b or M1c).
III. To compare the positive predictive value (PPV) per-patient in patients with lesion validation (follow-up imaging or biopsy).
Patients receive gallium Ga 68 gozetotide intravenously (IV). After 50-100 minutes, patients undergo whole body PET/CT.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||22 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Head-to-Head Comparison of 68Ga-PSMA-11 PET/CT With 99mTc-MDP Bone Scan and CT for Detection of M1b Disease in Prostate Cancer Patients With Biochemical Progression During ADT|
|Actual Study Start Date :||June 16, 2021|
|Actual Primary Completion Date :||October 18, 2022|
|Actual Study Completion Date :||October 18, 2022|
Experimental: Diagnostic (68Ga-PSMA-11 PET/CT)
Patients receive gallium Ga 68 gozetotide IV. After 50-100 minutes, patients undergo whole body PET/CT.
Procedure: Computed Tomography
Other: Gallium Ga 68 Gozetotide
Procedure: Positron Emission Tomography
- Per-patient detection rate of gallium Ga 68 gozetotide (68Ga-PSMA-11) positron emission tomography (PET)/computed tomography (CT) [ Time Frame: Up to 4 years ]68Ga-PSMA-11 PET will be compared to bone scan/CT for M1b disease in prostate cancer patients progressing during androgen deprivation therapy. Patients who have at least one positive bone lesion will be rated positive. Patients will be treated as binary categorization. The analysis of the primary objective will utilize the McNemar's test to compare the detection rate between the imaging techniques.
- Number of lesions found by PSMA PET and bone scan + CT [ Time Frame: Up to 4 years ]Will be compared using a paired samples t-test.
- Rate of M1 detection [ Time Frame: Up to 4 years ]Will be compared between the two modalities, defined as the number of patients with positive finding(s) for M1 disease (M1a or M1b or M1c), will utilize the McNemar's test for paired proportions.
- Per-patient positive predictive value (PPV) [ Time Frame: Up to 4 years ]Per-patient PPV estimates (with 95% confidence interval), defined as the number true positive findings the total number of positive cases (TP + FP). The lesions will be considered true positive on the basis of biopsy information, follow-up imaging, or changes in prostate specific antigen (PSA) levels. This information will only be available in a small subset of patients.
- PSA progression-free survival (PFS) [ Time Frame: Up to 4 years ]Univariate Cox proportional hazards models for PFS will be constructed with models containing various patient characteristics as well as PSMA PET parameters and bone scan parameters. Hazard ratios with 95% confidence intervals as well as p-values will be tabulated. Next, will explore multivariate models (using LASSO variable selection) including terms for important baseline characteristics as well as PSMA parameters or bone scan parameters and will extract the survival concordance indices from each of these models and compare them.
- Overall survival (OS) [ Time Frame: Up to 4 years ]Univariate Cox proportional hazards models for OS will be constructed with models containing various patient characteristics as well as PSMA PET parameters and bone scan parameters. Hazard ratios with 95% confidence intervals as well as p-values will be tabulated. Next, will explore multivariate models (using LASSO variable selection) including terms for important baseline characteristics as well as PSMA parameters or bone scan parameters and will extract the survival concordance indices from each of these models and compare them.
- Incidence of adverse events [ Time Frame: Up to 4 years ]Assessed using Common Terminology Criteria for Adverse Events version 4.03.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||Male|
|Gender Based Eligibility:||Yes|
|Gender Eligibility Description:||Eligibility requires prostrate gland|
|Accepts Healthy Volunteers:||No|
- Patient with biochemical progression during ADT or combination therapies including ADT who are referred for imaging evaluation (prostate specific antigen [PSA] level >= 1 ng/ml that has increased on at least 2 successive occasions at least 1 weak apart)
Patients with bone scan scheduled or performed
- Within 30 days of the PSMA PET, without any new prostate cancer (PCa) therapy in between
- Bone scans performed at University of California, Los Angeles (UCLA) and external institutions are eligible if Digital Imaging and Communications in Medicine (DICOM) images can be obtained, imported, and anonymized
- Patients enrolled in other clinical trials are eligible if they satisfy all other criteria of eligibility
- Patients or their legal representatives must have the ability to read, understand and provide written informed consent
- Initiation of a new therapy between the PSMA PET/CT and the bone scans
- Inability to provide written informed consent
- Known inability to remain still and lie flat for duration of each imaging procedure (about 30 minutes)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04928820
|United States, California|
|University of California at Los Angeles / Jonsson Comprehensive Cancer Center|
|Los Angeles, California, United States, 90095|
|Principal Investigator:||Jeremie Calais, MD||UCLA / Jonsson Comprehensive Cancer Center|
|Responsible Party:||Jonsson Comprehensive Cancer Center|
|Other Study ID Numbers:||
NCI-2021-03575 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
|First Posted:||June 16, 2021 Key Record Dates|
|Last Update Posted:||October 21, 2022|
|Last Verified:||October 2022|
|Studies a U.S. FDA-regulated Drug Product:||Yes|
|Studies a U.S. FDA-regulated Device Product:||No|
|Product Manufactured in and Exported from the U.S.:||No|
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Genital Neoplasms, Male
Neoplasms by Site
Genital Diseases, Male
Male Urogenital Diseases
Gallium 68 PSMA-11
Molecular Mechanisms of Pharmacological Action
Calcium Chelating Agents